Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Anal Toxicol ; 31(9): 581-7, 2007.
Article in English | MEDLINE | ID: mdl-18093417

ABSTRACT

The concentration of drugs and metabolites in cerebrospinal fluid (CSF) and blood were determined in 282 autopsied cases using liquid-liquid extraction techniques and gas chromatographic analyses. All drugs were confirmed in one matrix by gas chromatography-mass spectrometry. CSF/blood ratios were used to compare the two biological fluids. Classes of drugs evaluated in this study included: benzodiazepines, anticonvulsants, sedatives, opioids, antidepressants, anesthetics, and antihistamines. The majority of the drugs tested were readily detected in CSF specimens. The average CSF/blood ratio for most drugs was in the range of 0.05-0.50. Interpretation of these results is difficult because protein binding, half-life, hydrophobic properties, and pKa of a drug, in addition to survival time after drug use, influence the CSF/blood ratio. While CSF specimens do provide a viable alternative testing matrix when blood specimens are not available, they should not be used to estimate blood drug concentrations.


Subject(s)
Pharmaceutical Preparations/blood , Pharmaceutical Preparations/cerebrospinal fluid , Analgesics, Opioid/blood , Analgesics, Opioid/cerebrospinal fluid , Anesthetics/blood , Anesthetics/cerebrospinal fluid , Anti-Inflammatory Agents, Non-Steroidal/blood , Anti-Inflammatory Agents, Non-Steroidal/cerebrospinal fluid , Anticonvulsants/blood , Anticonvulsants/cerebrospinal fluid , Antidepressive Agents/blood , Antidepressive Agents/cerebrospinal fluid , Autopsy , Benzodiazepines/blood , Benzodiazepines/cerebrospinal fluid , Histamine H1 Antagonists/blood , Histamine H1 Antagonists/cerebrospinal fluid , Humans , Hypnotics and Sedatives/blood , Hypnotics and Sedatives/cerebrospinal fluid
2.
J Inherit Metab Dis ; 27(2): 291-3, 2004.
Article in English | MEDLINE | ID: mdl-15243989

ABSTRACT

Deficiency of succinic semialdehyde dehydrogenase (SSADH) is a rare neurometabolic disorder with accumulation of 4-hydroxybutyric acid (4-HBA) as a biochemical hallmark. We present a boy with an unresolved severe neurological disorder and intermittent elevation of 4-HBA in serum and CSF which was later shown to result from iatrogenic administration of 4-HBA for sedation purposes.


Subject(s)
Aldehyde Oxidoreductases/deficiency , Consciousness Disorders/chemically induced , Hydroxybutyrates/adverse effects , Hypnotics and Sedatives/adverse effects , Metabolism, Inborn Errors/diagnosis , Child , Consciousness Disorders/diagnosis , Consciousness Disorders/metabolism , Humans , Hydroxybutyrates/blood , Hydroxybutyrates/cerebrospinal fluid , Hypnotics and Sedatives/blood , Hypnotics and Sedatives/cerebrospinal fluid , Male , Metabolism, Inborn Errors/metabolism , Succinate-Semialdehyde Dehydrogenase
3.
Neuroreport ; 10(5): 947-51, 1999 Apr 06.
Article in English | MEDLINE | ID: mdl-10321465

ABSTRACT

While preliminary studies associated oleamide with sleep regulation, we now characterize the involvement of oleamide in sleep using a number of techniques. Peripheral administration of oleamide to rats dose dependently suppressed motor activity in the open field, with an ED50 of 17+/-1.5mg/kg for the decrease in distance traveled. Moreover, endogenous oleamide concentrations increased 3- to 4-fold in the cerebrospinal fluid of rats sleep-deprived for 6 h or longer. Oleamide also decreased sleep latency to 44-64% of control values without altering other sleep parameters. Unlike many putative endogenous sleep-inducing agents, oleamide potently induces behavioral and electroencephalographic manifestations of sleep. Moreover, its endogenous concentrations and temporal associations are consistent with previous reports of its enhancement of serotonergic and GABAergic neurotransmission, which may be involved in sleep induction.


Subject(s)
Hypnotics and Sedatives/pharmacology , Oleic Acids/pharmacology , Sleep/drug effects , Animals , Behavior, Animal/drug effects , Electroencephalography , Hypnotics and Sedatives/blood , Hypnotics and Sedatives/cerebrospinal fluid , Male , Motor Activity/drug effects , Oleic Acids/blood , Oleic Acids/cerebrospinal fluid , Rats , Rats, Sprague-Dawley , Reaction Time/drug effects , Sleep/physiology , Sleep Deprivation/physiology
4.
Pediatr Dent ; 20(5): 321-6, 1998.
Article in English | MEDLINE | ID: mdl-9803431

ABSTRACT

PURPOSE: The purpose of this investigation was to compare the pharmacokinetics of midazolam following intravenous, intranasal drop, and nasal-atomizer administration in beagle dogs. METHODS: Six animals weighing 9-13 kg were used in a repeated-measure design, group assignment based on route of drug administration. Midazolam (1.5 mg/kg) was administered with the delivery route based on group assignment. Blood samples were obtained at baseline and at 1, 3, 5, 7, 10, 15, 20, 30, and 45 min after administration. Cerebrospinal fluid samples (CSF) were obtained at 5 and 10 min after administration. Plasma and CSF concentrations of midazolam were determined by electron-capture gas-liquid chromatography. RESULTS: Comparison between groups and over time demonstrated that both nasal routes resulted in significantly higher CSF concentrations relative to corresponding plasma levels, and that nasal-atomizer administration produced significantly higher CSF concentrations compared to the drop approach.


Subject(s)
Hypnotics and Sedatives/pharmacokinetics , Midazolam/pharmacokinetics , Administration, Intranasal , Animals , Biological Availability , Chromatography, Gas , Dogs , Evaluation Studies as Topic , Follow-Up Studies , Hypnotics and Sedatives/administration & dosage , Hypnotics and Sedatives/blood , Hypnotics and Sedatives/cerebrospinal fluid , Injections, Intravenous , Midazolam/administration & dosage , Midazolam/blood , Midazolam/cerebrospinal fluid , Nebulizers and Vaporizers , Prospective Studies
5.
Eur Neurol ; 39(4): 223-8, 1998.
Article in English | MEDLINE | ID: mdl-9635473

ABSTRACT

Barbiturate coma is initiated in brain-injured patients whenever elevated intracranial pressure remains unresponsive to other therapeutical strategies. However, barbiturates alter cortical activity resulting in difficulties in clinical evaluation. Therefore, we investigated the impact of long-term thiopental administration on responsiveness to exteroceptive stimuli in relation to pharmacokinetics of thiopental in CSF and serum. Long-term infusion increases thiopental levels which remain elevated for 6 and 9 days in CSF and serum, respectively, after termination of its administration. Prolonged unresponsiveness to exteroceptive stimuli correlates with persisting thiopental in CSF and serum. Thus, quantitative analysis of thiopental in serum becomes indispensable in predicting the length of drug-induced neurological impairment and in avoiding misinterpretation of the neurological status.


Subject(s)
Brain Injuries/drug therapy , Critical Care/methods , Hypnotics and Sedatives/pharmacokinetics , Thiopental/pharmacokinetics , Adolescent , Adult , Electroencephalography , Female , Humans , Hypnotics and Sedatives/blood , Hypnotics and Sedatives/cerebrospinal fluid , Infusions, Intravenous , Intracranial Pressure , Male , Middle Aged , Thiopental/blood , Thiopental/cerebrospinal fluid , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...